

New Daily Persistent Headache



Dr. Amy Wilcox Voigt

*Neurology Clerkship Director
Associate Professor of Neurology*



Disclosures

- I have served as compensated speaker for Teva, Biogen and Abbvie
- There are no FDA approved therapies for New Daily Persistent Headache



Objectives

- To describe the clinical features, etiology and associated features of New Daily Persistent Headache (NDPH)
- To address differential diagnosis and mimics of NDPH
- Address management of NDPH



Patient Case - classic

- 32 yo woman presents to clinic with complaint of 'constant headache'
- Specifically knows it started while she was standing at whiteboard, speaking and teaching her 3rd grade class
- Felt it started as 'achy but not severe'. She took ibuprofen while at school and was able to continue working that day
- Non migranous, no other features, but headache has been there 'ever since, every day, all day'
- Has not responded to OTC medication, allergy medication, sumatriptan that was prescribed by her Ob-Gyn



Criteria

Table 1 International Classification of Headache Disorders, 2nd edition criteria for new daily-persistent headache^a

- A. Headache for more than 3 months fulfilling criteria B-D^a
- B. Headache is daily and unremitting from onset or less than 3 days from onset
- C. At least 2 of the following pain characteristics:
 - 1. Bilateral location
 - 2. Pressing/tightening (nonpulsating) quality
 - 3. Mild or moderate intensity
 - 4. Not aggravated by routine physical activity such as walking or climbing stairs
- D. Both of the following:
 - 1. No more than one of photophobia, phonophobia, or mild nausea
 - 2. Neither moderate or severe nausea or vomiting
- E. Not attributed to another disorder

^aThe revised criteria for new daily-persistent headache⁵ do not require C or D.



Clinical Features:

- Headache Features:
 - Clearly remembered onset
 - 42% remember exact day
 - 79% remember exact month
 - Bilateral pain, similar to CM or CTTH
 - Lasting at least 3 months
 - Prior to 3 months is 'probable' NDPH
- Associated Features:
 - Nausea, photo/phonophobia
 - Autonomic symptoms
 - Allodynia
 - Co-existing anxiety or depression



Another Patient Case

- 46 year old female physician, seen for 'constant headache x 9 months'.
- Was previously a migraine patient over previous 10 years – migraines responded to Topamax 50mg QD and fioricet or rizatriptan prn. Migraines improved significantly after stopping oral contraceptives. She discontinued topamax and was only seen for annual appointments.
- She developed acute COVID infection 9 months prior. During infection she had mild symptoms of congestion, fever, malaise, mild headache for 7-10 days. Most COVID symptoms resolved but headache persisted. Also has continued malaise, muscle aches and new onset blood pressure instability.
- Describes headache as present upon awakening, worsening as day continues, mild relief with resting but no resolution.
- Mild photo and phonophobia but no nausea; not as severe as previous migraines
- Has not responded to OTC, rizatriptan, topamax; is now using Fioricet 1-2/day



Associations

- Infection (10-30 %)
 - EBV, CMV, HSV, COVID
 - Seasonal
 - Migraine progression in post infectious
- Stressful life events (10-20%)
 - Onset of school year
- Vaccines (Rare)
 - VZV, influenza, HPV
 - Covid (22-29% vs 10-12% in placebo)
- Other
 - Hypothyroidism
 - Anti-depressant wean
 - Secondary causes – hypermobility syndromes, valsalva, post-surgical/intubation



Epidemiology

- Prevalence
 - 0.03-.1% general population
 - 1.7-10.8% adult headache clinic
 - 13-36% pediatric neurology clinic
- Incidence
 - 17-19% increase after onset COVID, terrorist attacks
- Female:Male
 - 1.1-2.6: 1
- Age
 - 10-50s range age of onset
 - 30s-40s median age
- Geography
 - Most regions/ no specific ethnic predominance
- Co-Morbidities
 - 62.2% depression
 - 45.9% anxiety
 - Sleep disturbance in pediatric onset



Diagnostic Testing

- Genetics
 - unknown
- Serum
 - Thyroid levels – consider hypothyroidism mimic
 - COVID biomarkers for long COVID
- CSF
 - TNF- α (non-specific)
- Structural Imaging
 - MRI 'abnormalities' present in 8-13% - White matter changes

- Functional Imaging

- decreased blood flow in multiple right hemisphere cortical areas
 - decreased thickness in multiple cortical areas
 - Altered functional connectivity in areas involved in emotional and cognitive pain regulation



LSU Health New Orleans

School of Medicine

Rozen T et al, Headache 2007 Peng KP et al, Cephalgia

2011 Bai X et al J Headache Pain 2022

Department of
Neurology



Patient Case— our 32 year old teacher

- Physical Exam - grossly normal
 - Frustrated and occasionally emotional while discussing history but otherwise completely normal neurologic exam
- Labs
 - Done by Ob-GYN prior to visit and all wnl
 - *Baseline CNC, CMP, Thyroid panel, ESR/CRP, ANA*
 - *COVID negative*
 - *'Hormones normal'*
- Imaging
 - Brain MRI with Contrast essentially wnl
 - *few scattered white matter lesions*
 - *No evidence of CSF leak*



Patient Case– our 46 year old physician

- Exactly the same labs and Imaging
- LP with normal opening pressure, tested for biomarkers as part of CDC long COVID study
- Autonomic insufficiency found through cardiology diagnostics



Evaluation

- History -
 - look for pre migraine and possibility of evolution
 - Tempo of onset – is this truly 0 to 60
- Physical Examination
 - any evidence of hypermobility, Trendelenburg
- Neuroimaging
 - MRI brain +/- contrast
 - MRI spine
- Labs
 - Thyroid function, ESR/CRP, Lyme (select)



Treatment

- General consensus is to treat NDPH based on its phenotype
 - migraine vs tension vs cervicalgia
 - 40–41% across all studies
- Acute treatments:
 - Traditionally triptans, consider gepants
 - TTH – NSAID, muscle relaxant
 - Devices – not significant evidence
- Preventive treatments:
 - All have 'some evidence' – TCAs, TPM, VPA, B-Blockers, anti-CGRP, onobotA
 - Nerve Blocks

- Other strategies

- Doxycycline, low-dose naltrexone – no peer reviewed evidence



LSU Health New Orleans
School of Medicine

Rozen T et al, Headache 2007, 2009 Peng KP et al, Cephalalgia 2010 Greene BK et al, Pediatr Neurology 2021
Prakash S Shah ND, J Headache Pain 2010 Reidy BL et al Cephalalgia 2020 Buture A Cephalalgia 2023 Reidy BL

Department of
Neurology



Treatment

- Behavioral Therapies
 - Outside CBT
- Patient Counseling – What starts the headache is not always what pushes it
 - Address patient specific goals –
 - may not cure, but make manageable
 - Medication overuse
- Neurologic management of other conditions
 - POTS, fibromyalgia, erythromyelgia, long COVID



Prognosis

Multiple studies – resolution from 68%-86% in 'best outcome'

- In all studies, the sooner patient had intervention, the better the long term outcome



LSU Health New Orleans
School of Medicine

Vanast WJ, Headache 1986 Peng KP et al, Cephalalgia
2011 Robbins MS et al, Neurology 2012 Kim J et al J
Headache Pain 2016

Department of
Neurology



Patient Follow Up

- 32 year old teacher
 - Non responsive to many oral preventives; currently on combination onobotA and anti-CGRP with daily headache but reduced pain
 - -uses OTC excederin no more than 3x/week for breakthrough and has returned to work
- 46 year old physician
 - Best response has been to atogepant after having severe site reactions to injected anti-CGRP, with gepant for severe headache
 - Also has shown overall benefit with treatment of autonomic insufficiency
 - Sees behavioral therapist and has returned to work



Summary: New Daily Persistent Headache

- Daily headache that starts acutely and is diagnosed after 3 months
- Exclude other primary or secondary headache diagnoses
 - SIH, CSF venous-fistulas
- Clinically can resemble Chronic migraine or tension type
- Likely due to multiple entities and is not one specific disorder
- Symptomatic treatment is same as acute and preventive for migraine



